Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin - Hinchcliff, Monique; Toledo, Diana M.; Taroni, Jaclyn N.; Wood, Tammara A.; Franks, Jennifer M.; Ball, Michael S.; Hoffmann, Aileen; Amin, Sapna M.; Tan, Ainah U.; Tom, Kevin; Nesbeth, Yolanda; Lee, Jungwha; et al. (Journal of investigative dermatology, 2018)
Keywords: Adult; Biopsy; Case-Control Studies; Cell Count; Chemokine CCL2 - immunology; Chemokine CCL2 - metabolism; Female; Gene Expression Profiling; Humans; Immunosuppressive Agents - pharmacology; Immunosuppressive Agents - therapeutic use; Longitudinal Studies; Male; Middle Aged; Mycophenolic Acid - pharmacology; Mycophenolic Acid - therapeutic use; Myeloid Cells - drug effects; Myeloid Cells - immunology; Prospective Studies; Scleroderma, Systemic - drug therapy; Scleroderma, Systemic - immunology; Scleroderma, Systemic - pathology; Skin - cytology; Skin - drug effects; Skin - immunology; Skin - pathology; Transcriptome - drug effects; Transcriptome - immunology; Treatment Outcome; SSc; mDC; NES; MMF; mRSS; DC